Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA
KZIA Stock Chart & Stats
$6.44
-$0.01(-0.57%)
At close: 4:00 PM EST
$6.44
-$0.01(-0.57%)
Day’s Range― - ―
52-Week Range$2.86 - $17.40
Previous CloseN/A
Volume31.49K
Average Volume (3M)209.48K
Market Cap
$83.21M
Enterprise Value-$47.24M
Total Cash (Recent Filing)$69.39M
Total Debt (Recent Filing)$98.71K
Price to Earnings (P/E)―
Beta1.73
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,335,992
10 Day Avg. Volume60,839
30 Day Avg. Volume209,481
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.26
Price to Sales (P/S)248.45
P/FCF Ratio-0.79
Enterprise Value/Market Cap-0.57
Enterprise Value/Revenue-2.40K
Enterprise Value/Gross Profit-2.40K
Enterprise Value/Ebitda2.60
Forecast
1Y Price Target
$19.00Price Target Upside195.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPaxalisib combined with pembrolizumab and chemotherapy produced partial responses and a confirmed complete metabolic response in very late‑stage, multi‑organ metastatic triple‑negative breast cancer patients, indicating meaningful clinical activity.
Indication Expansion PotentialClinical progress in triple‑negative and HER2‑positive breast cancer could materially broaden paxalisib's commercial opportunity beyond the lead glioblastoma indication if larger trials confirm benefit.
Safety And TolerabilityPaxalisib showed a favorable tolerability profile in combination with pembrolizumab and chemotherapy, with no severe adverse events reported, supporting continued development.
Bears Say
Clinical Outcome UncertaintyFailure of the paxalisib combination to demonstrate improved progression‑free survival versus historical benchmarks for pembrolizumab plus chemotherapy would materially dampen the stock's outlook.
Market Sentiment And VolatilityShare price weakness appears driven by short‑term selling pressure rather than underlying clinical progress, creating heightened volatility risk for investors.
Partnership, Financial And Intellectual Property RiskCommercial, financial, partnership, or intellectual property challenges—such as difficulty securing collaborations or defending key patents—could constrain valuation and investor confidence.
Kazia Therapeutics News
KZIA FAQ
What was Kazia Therapeutics Limited’s price range in the past 12 months?
Kazia Therapeutics Limited lowest stock price was $2.86 and its highest was $17.40 in the past 12 months.
What is Kazia Therapeutics Limited’s market cap?
Kazia Therapeutics Limited’s market cap is $83.21M.
When is Kazia Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Kazia Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Kazia Therapeutics Limited overvalued?
According to Wall Street analysts Kazia Therapeutics Limited’s price is currently Undervalued.
Does Kazia Therapeutics Limited pay dividends?
Kazia Therapeutics Limited does not currently pay dividends.
What is Kazia Therapeutics Limited’s EPS estimate?
Kazia Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kazia Therapeutics Limited have?
Kazia Therapeutics Limited has 11,335,992 shares outstanding.
What happened to Kazia Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kazia Therapeutics Limited?
Currently, no hedge funds are holding shares in KZIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kazia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (195.03% Upside)
$19.00 (195.03% Upside)
Hedge Fund Trend
Decreased
By 36.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.8%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-73.42%
12-Months-Change
Fundamentals
Return on Equity
-116.86%
Trailing 12-Months
Asset Growth
327.60%
Trailing 12-Months
Company Description
Kazia Therapeutics Limited
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Stock 12 Month Forecast
Average Price Target
$19.00
▲(195.03% Upside)
Technical Analysis
Phio Pharmaceuticals
―
XTL Biopharmaceuticals Sponsored ADR
―
Marker Therapeutics
―
―
TransCode Therapeutics
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
18.93% Other Institutional Investors
81.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---